Postpartum bleeding

Short description: Loss of blood following childbirth

Postpartum bleeding

Other names| Postpartum hemorrhage
A non-pneumatic anti-shock garment (NASG)
Specialty| Obstetrics
Symptoms| Significant blood loss after childbirth, increased heart rate, feeling faint upon standing, increased breath rate[1][2]
Causes| Poor contraction of the uterus, not all the placenta removed, tear of the uterus, poor blood clotting[2]
Risk factors| Anemia, Asian ethnicity, more than one baby, obesity, age older than 40 years[2]
Prevention| Oxytocin, misoprostol[2]
Treatment| Intravenous fluids, non-pneumatic anti-shock garment, blood transfusions, ergotamine, tranexamic acid[2][3]
Prognosis| 3% risk of death (developing world)[2]
Frequency| 8.7 million (global)[4] / 1.2% of births (developing world)[2]
Deaths| 83,100 (2015)[5]

Postpartum bleeding or postpartum hemorrhage (PPH) is significant blood loss following childbirth. It is the most common cause of maternal death worldwide, disproportionately affecting developing countries.[6] Definitions and criteria for diagnosis are highly variable.[2][7] PPH is defined by the World Health Organization as "blood loss of 500 ml or more within 24 hours after birth",[8] though signs of shock (insufficient blood flow) have also been used as a definition.[7] Some bleeding after childbirth is normal and is called lochia. It is difficult to distinguish lochia from delayed PPH.[9]

Signs and symptoms of PPH may initially include: an increased heart rate, feeling faint upon standing, and an increased breathing rate. As more blood is lost, the patient may feel cold, blood pressure may drop, and they may become restless or unconscious.[1] In severe cases circulatory collapse, disseminated intravascular coagulation and death can occur. The condition can occur up to twelve weeks following delivery.[10]

The most common cause of PPH is insufficient contraction of the uterus following childbirth; this contraction normally stops the blood flow that supplies the fetus during pregnancy. Other causes are retained placenta, where the placenta is not expelled after childbirth; a tear of the uterus, cervix, or vagina; or poor blood clotting. PPH is more likely to occur in people who are Asian[clarification needed], are obese, previously had PPH or have an anemia, give birth to a large baby or more than one fetus, or are older than 40 years of age.[2] It also occurs more commonly following caesarean sections, those in whom medications are used to start labor, those requiring the use of a vacuum or forceps, and those who have an episiotomy.[2][11]

Prevention involves decreasing known risk factors including procedures associated with the condition, if possible, and giving the medication oxytocin to stimulate the uterus to contract shortly after the baby is born.[2] Misoprostol may be used instead of oxytocin in resource-poor settings.[2] Treatments may include: intravenous fluids, blood transfusions, and the medication ergotamine to cause further uterine contraction.[2] Efforts to compress the uterus using the hands may be effective if other treatments do not work.[2] The aorta may also be compressed by pressing on the abdomen.[2] The World Health Organization has recommended the non-pneumatic anti-shock garment to help until other measures such as surgery can be carried out.[2] Tranexamic acid has also been shown to reduce the risk of death,[12] and has been recommended within three hours of delivery.[13]

In the developing world about 1.2% of deliveries are associated with PPH and when PPH occurred about 3% of women died.[2] It is responsible for 8% of maternal deaths during childbirth in developed regions and 20% of maternal deaths during childbirth in developing regions.[10] Globally it occurs about 8.7 million times and results in 44,000 to 86,000 deaths per year making it the leading cause of death during pregnancy.[4][2][14] About 0.4 women per 100,000 deliveries die from PPH in the United Kingdom while about 150 women per 100,000 deliveries die in sub-Saharan Africa.[2] Rates of death have decreased substantially since at least the late 1800s in the United Kingdom.[2]

## Contents

* 1 Definition
* 2 Signs and symptoms
* 3 Causes
* 4 Prevention
* 5 Management
* 5.1 Medication
* 5.2 Surgery
* 5.3 Medical devices
* 5.4 Protocol
* 6 Epidemiology
* 7 References
* 8 External links

## Definition

Depending on the source, primary postpartum bleeding is defined as blood loss in excess of 500 ml following vaginal delivery or 1000 mL following caesarean section in the first 24 hours following birth. Others have defined the condition as blood loss of greater than 1000 mL after either delivery method, or any amount of blood loss with signs and symptoms of hypovolemia.[10] Secondary postpartum bleeding is that which occurs after the 24 hours up to 12 weeks after childbirth.[10]

## Signs and symptoms

Symptoms generally include heavy bleeding from the vagina that doesn't slow or stop over time.[15] Initially there may be an increased heart rate, feeling faint upon standing, and an increased respiratory rate.[1] As more blood is lost, the patient may feel cold, blood pressure may drop, and they may become unconscious.[1]

Signs and symptoms of circulatory shock may also include blurry vision, cold and clammy skin, confusion, and feeling sleepy or weak.[1][15]

## Causes

Causes of postpartum hemorrhage[16] Cause  | Incidence

|

Uterine atony  | 70%
Trauma  | 20%
Retained tissue  | 10%
Coagulopathy  | 1%

Causes of postpartum hemorrhage are uterine atony, trauma, retained placenta or placental abnormalities, and coagulopathy, commonly referred to as the "four Ts":[16]

* Tone: uterine atony is the inability of the uterus to contract and may lead to continuous bleeding. Retained placental tissue and infection may contribute to uterine atony. Uterine atony is the most common cause of postpartum hemorrhage.[17]
* Trauma: Injury to the birth canal which includes the uterus, cervix, vagina and the perineum which can happen even if the delivery is monitored properly. The bleeding is substantial as all these organs become more vascular during pregnancy.
* Tissue: retention of tissue from the placenta or fetus as well as placental abnormalities such as placenta accreta and percreta may lead to bleeding.
* Thrombin: a bleeding disorder occurs when there is a failure of clotting, such as with diseases known as coagulopathies.

Risk factors with a strong association with postpartum hemorrhage included anemia, previous postpartum hemorrhage, caesarean birth, female genital mutilation, sepsis, no antenatal care, multiple pregnancy, placenta praevia, assisted reproductive technology use, macrosomia with a birthweight of more than 4500 g, and shoulder dystocia.[18]

Risk factors with moderate association with postpartum hemorrhage included obesity defined as BMI ≥30 kg/m2, COVID-19 infection, gestational diabetes, polyhydramnios, pre-eclampsia, and antepartum hemorrhage.[19]

Other risk factors include endometriosis,[20] fever during pregnancy, bleeding before delivery, and heart disease.[11]

## Prevention

Oxytocin is typically used right after the delivery of the baby to prevent PPH.[2] Misoprostol may be used in areas where oxytocin is not available.[2] Early clamping of the umbilical cord does not decrease risks and may cause anemia in the baby, and thus is usually not recommended.[2] Tranexamic acid does not prevent PPH and likelihood to receive blood transfusion.[21]

Active management of the third stage is a method of shortening the stage between when the baby is born and when the placenta is delivered.[22] This stage is when the mother is at risk of having a PPH. Active management involves giving a drug which helps the uterus contract before delivering the placenta by a gentle but sustained pull on the umbilical cord whilst exerting upward pressure on the lower abdomen to support the uterus (controlled cord traction).[22]

Active management of the third stage of labor with uterotonics (oxytocin or Misoprostol) and gentle umbilical cord traction have been shown to reduce the incidence of PPH by 66%.[10]

Another method of active management which is no longer recommended is fundal pressure during the delivery of the placenta. A review into this method found no benefit to its use and advises only controlled cord traction because fundal pressure can cause the mother unnecessary pain.[22] Allowing the cord to drain appears to shorten the third stage and reduce blood loss but evidence around this subject is not strong enough to draw solid conclusions.[23]

Nipple stimulation and breastfeeding triggers the release of natural oxytocin in the body, therefore it is thought that encouraging the baby to suckle soon after birth may reduce the risk of PPH for the mother.[24] A review looking into this did not find enough good research to say whether or not nipple stimulation did reduce PPH. More research is needed to answer this question.[24]

## Management

Performing a uterine massage Side view of a uterine massage with underlying anatomy

Uterine massage is a simple first line treatment as it helps the uterus to contract to reduce bleeding.[25] Although the evidence around the effectiveness of uterine massage is inconclusive, it is common practice after the delivery of the placenta.[25]

### Medication

Intravenous or intramuscular oxytocin is the drug of choice for postpartum hemorrhage.[8][26] Ergotamine may also be used.[2] Combination of oxytocin plus ergometrin and misoprostol plus oxytocin reduce the likelihood of blood loss of 500 mL, however either carbetocin or injectable prostaglandins and ergometrine make little or no difference.[27] Combination of misoprostol plus oxytocin probably reduces the need for additional uterotonics and the need for blood transfusion, while carbetocin probably makes little difference to blood transfusion.[27]

Oxytocin helps the uterus to contract quickly and the contractions to last longer.[28] It is the first line treatment for PPH when its cause is the uterus not contracting well.[29] A combination of syntocinon and ergometrine is commonly used as part of active management of the third stage of labour.[30] This is called syntometrine. Syntocinon alone lowers the risk of PPH.[31] Based on limited research available it is unclear whether syntocinon or syntometrine is most effective in preventing PPH but adverse effects are worse with syntometrine making syntocinon a more attractive option.[31] Ergometrine also has to be kept cool and in a dark place so that it is safe to use.[32] It may reduce the risk of PPH by improving the tone of the uterus when compared with no treatment, however it must be used with caution due to its effects of raising blood pressure and worsening pain.[32] More research would be useful in determining the best doses of ergometrine[32] and syntocinon.[30]

Oxytocin requires refrigeration, which may not always be available, particularly in low-resourced settings.[33] When oxytocin is not available, misoprostol can be used.[29] Misoprostol does not need to be kept at a certain temperature and research into its effectiveness in reducing blood loss appears promising when compared with a placebo in a setting where it is not appropriate to use oxytocin.[33] Misoprostol can cause unpleasant side effects such as very high body temperatures and shivering.[34] Lower doses of misoprostol appear to be safer and cause less side effects.[34]

Giving oxytocin in a solution of saline into the umbilical vein is a method of administering the drug directly to the placental bed and uterus.[35] However quality of evidence around this technique is poor and it is not recommended for routine use in the management of the third stage.[35] More research is needed to ascertain whether this is an effective way of administering uterotonic drugs.[35] As a way of treating a retained placenta, this method is not harmful and has shown low certainty evidence of effectiveness.[36]

Carbetocin compared with oxytocin produced a reduction in women who needed uterine massage and further uterotonic drugs for women having caesarean sections.[37] There was no difference in rates of PPH in women having caesarean sections or women having vaginal deliveries when given carbetocin.[37] Carbetocin appears to cause less adverse effects. More research is needed to find the cost effectiveness of using carbetocin.[37]

Tranexamic acid, a clot stabilizing medication, makes little to no difference to blood loss, the risk of severe morbidity or additional surgical interventions.[38] A 2017 trial found that it decreased the risk of death from bleeding from 1.9% to 1.5% in women with postpartum bleeding.[12] The benefit was greater when the medication was given within three hours.[12]

In some countries, such as Japan, methylergometrine and other herbal remedies are given following the delivery of the placenta to prevent severe bleeding more than a day after the birth. However, there is not enough evidence to suggest that these methods are effective.[39]

### Surgery

Surgery may be used if medical management fails or in case of cervical lacerations, tears in the uterine wall or a uterine rupture. Methods used may include uterine artery ligation, ovarian artery ligation, internal iliac artery ligation, selective arterial embolization, B-lynch suture, and hysterectomy.[40][41][42][43] Bleeding caused by traumatic causes should be managed by surgical repair. When there is bleeding due to uterine rupture a repair can be performed but most of the time a hysterectomy is needed.[citation needed]

There is currently no reliable evidence from randomised clinical trials about the effectiveness or risks of mechanical and surgical methods of treating postpartum bleeding.[44]

In those with placenta accreta (in which the placenta invades into the muscular layer of the uterus) planned caesarian delivery is recommended due to the very high risk of PPH although the optimal time for planned delivery is not well established with the American College of Obstetricians and Gynecologists recommending planned caesarian at delivery between 34 weeks and 35 weeks and 6 days gestation and the Royal College of Obstetricians and Gynaecologists recommending it between 35 and 36 weeks and 6 days.[10] A hysterectomy is sometimes required, or planned, after the planned delivery.[10][45]

### Medical devices

The World Health Organization recommends the use of a device called the non-pneumatic anti-shock garment (NASG) for use in delivery activities outside of a hospital setting, the aim being to improve shock in a mother with obstetrical bleeding long enough to reach a hospital.[46] External aortic compression devices (EACD) may also be used.[47][48]

Uterine balloon tamponade (UBT) can improve postpartum bleeding.[49] Inflating a Sengstaken–Blakemore tube in the uterus successfully treats atonic postpartum hemorrhage refractory to medical management in approximately 80% of cases.[50] Such procedure is relatively simple, inexpensive and has low surgical morbidity.[50] A Bakri balloon is a balloon tamponade specifically constructed for uterine postpartum hemorrhage.[51] While effective, commercially available devices may be expensive for settings in which postpartum hemorrhage is most common. Low-cost devices, such as the ESM-UBT, have been shown to be effective without the need for operative intervention.[52][53][54] Uterine balloon tamponade devices may be left in place for up to 24 hours in the treatment of PPH.[10]

Uterine and vaginal packing are not recommended in the treatment of PPH and are associated with a high risk of infection.[10]

### Protocol

Protocols to manage postpartum bleeding are recommended to ensure the rapid giving of blood products when needed.[55] A detailed stepwise management protocol has been introduced by the California Maternity Quality Care Collaborative.[56] It describes four stages of obstetrical hemorrhage after childbirth and its application reduces maternal mortality.[57]

* Stage 0: normal - treated with fundal massage and oxytocin.
* Stage 1: more than normal bleeding - establish large-bore intravenous access, assemble personnel, increase oxytocin, consider use of methergine, perform fundal massage, prepare 2 units of packed red blood cells.
* Stage 2: bleeding continues - check coagulation status, assemble response team, move to operating room, place intrauterine balloon, administer additional uterotonics (misoprostol, carboprost tromethamine), consider: uterine artery embolization, dilatation and curettage, and laparotomy with uterine compression stitches or hysterectomy.
* Stage 3: bleeding continues - activate massive transfusion protocol, mobilize additional personnel, recheck laboratory tests, perform laparotomy, consider hysterectomy.

A Cochrane review suggests that active management (use of uterotonic drugs, cord clamping and controlled cord traction) during the third stage of labour may reduce severe bleeding and anemia.[58] However, the review also found that active management increased the patient's blood pressure, nausea, vomiting, and pain. In the active management group more patients returned to hospital with bleeding after discharge, and there was also a reduction in birthweight due to infants having a lower blood volume. The effects on the baby of early cord clamping was discussed in another review which found that delayed cord clamping improved iron stores longer term in the infants.[59] Although they were more likely to need phototherapy (light therapy) to treat jaundice, the improved iron stores are expected to be worth increasing the practice of delayed cord clamping in healthy term babies.[59]

For preterm babies (babies born before 37 weeks) a review of the research found that delaying cord clamping may lead to fewer babies with bleeding in the brain, compared to early cord clamping.[60]

Another Cochrane review looking at the timing of the giving oxytocin as part of the active management found similar benefits with giving it before or after the expulsion of the placenta.[61]

There is no good quality evidence on how best to treat a secondary PPH (PPH occurring 24 hrs or more after the birth).[62]

## Epidemiology

Methods of measuring blood loss associated with childbirth vary, complicating comparison of prevalence rates.[63] A systematic review reported the highest rates of PPH in Africa (27.5%), and the lowest in Oceania (7.2%), with an overall rate globally of 10.8%.[63] The rate in both Europe and North America was around 13%.[63] The rate is higher for multiple pregnancies (32.4% compared with 10.6% for singletons), and for first-time mothers (12.9% compared with 10.0% for women in subsequent pregnancies).[63] The overall rate of severe PPH (>1000 ml) was much lower at an overall rate of 2.8%, again with the highest rate in Africa (5.1%).[63]

## References

1. ↑ 1.0 1.1 1.2 1.3 1.4 Lynch, Christopher B- (2006). A textbook of postpartum hemorrhage: a comprehensive guide to evaluation, management and surgical intervention. Duncow: Sapiens Publishing. pp. 14–15. ISBN 978-0-9552282-3-0. https://books.google.com/books?id=AiIsuw5cga8C&pg=PA14.
2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 Weeks, A (January 2015). "The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?". BJOG: An International Journal of Obstetrics and Gynaecology 122 (2): 202–10. doi:10.1111/1471-0528.13098. PMID 25289730.
3. ↑ Cite error: Invalid `<ref>` tag; no text was provided for refs named `[`
4. ↑ 4.0 4.1 "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.". Lancet 388 (10053): 1545–1602. 8 October 2016. doi:10.1016/S0140-6736(16)31678-6. PMID 27733282.
5. ↑ "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.". Lancet 388 (10053): 1459–1544. 8 October 2016. doi:10.1016/s0140-6736(16)31012-1. PMID 27733281.
6. ↑ Cresswell, Jenny A; Alexander, Monica; Chong, Michael Y C; Link, Heather M; Pejchinovska, Marija; Gazeley, Ursula; Ahmed, Sahar M A; Chou, Doris et al. (April 2025). "Global and regional causes of maternal deaths 2009–20: a WHO systematic analysis" (in en). The Lancet Global Health 13 (4): e626–e634. doi:10.1016/S2214-109X(24)00560-6. PMID 40064189.
7. ↑ 7.0 7.1 Gibbs, Ronald S (2008). Danforth's obstetrics and gynecology (10th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 453. ISBN 978-0-7817-6937-2. https://books.google.com/books?id=v4krPhqFG8sC&pg=PA453.
8. ↑ 8.0 8.1 WHO recommendations for the prevention and treatment of postpartum haemorrhage.. Geneva: World Health Organization. 2012. ISBN 978-92-4-154850-2. https://iris.who.int/bitstream/handle/10665/75411/9789241548502_eng.pdf.
9. ↑ Fletcher, Susan; Grotegut, Chad A.; James, Andra H. (December 2012). "Lochia Patterns Among Normal Women: A Systematic Review" (in en). Journal of Women's Health 21 (12): 1290–1294. doi:10.1089/jwh.2012.3668. ISSN 1540-9996. http://www.liebertpub.com/doi/10.1089/jwh.2012.3668.
10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 Bienstock, Jessica L.; Eke, Ahizechukwu C.; Hueppchen, Nancy A. (29 April 2021). "Postpartum Hemorrhage". New England Journal of Medicine 384 (17): 1635–1645. doi:10.1056/NEJMra1513247. PMID 33913640.
11. ↑ 11.0 11.1 Lockhart, E (2015). "Postpartum hemorrhage: a continuing challenge.". Hematology. American Society of Hematology. Education Program 2015 (1): 132–7. doi:10.1182/asheducation-2015.1.132. PMID 26637712.
12. ↑ 12.0 12.1 12.2 Shakur, Haleema; Roberts, Ian; Fawole, Bukola (April 2017). "Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial". The Lancet 389 (10084): 2105–2116. doi:10.1016/S0140-6736(17)30638-4. PMID 28456509.
13. ↑ World Health Organization (October 2017). "Updated WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage". https://apps.who.int/iris/bitstream/handle/10665/259379/WHO-RHR-17.21-eng.pdf?sequence=1.
14. ↑ "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet 385 (9963): 117–71. 17 December 2014. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442.
15. ↑ 15.0 15.1 "Postpartum hemorrhage" (in en). http://www.marchofdimes.org/pregnancy/postpartum-hemorrhage.aspx.
16. ↑ 16.0 16.1 "Prevention and management of postpartum hemorrhage". American Family Physician 75 (6): 875–82. March 2007. PMID 17390600.
17. ↑ "Overview of postpartum hemorrhage". http://www.uptodate.com/contents/overview-of-postpartum-hemorrhage?source=search_result&search=post+partum+hemorrhage&selectedTitle=1~133.
18. ↑ Yunas, Idnan; Islam, Md Asiful; Sindhu, Kulandaipalayam N.; Devall, Adam J.; Podesek, Marcelina; Alam, Sayeda Sadia; Kundu, Shoumik; Mammoliti, Kristie-Marie et al. (2025-04-03). "Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis" (in English). The Lancet 405 (10488): 1468–1480. doi:10.1016/S0140-6736(25)00448-9. ISSN 0140-6736. PMID 40188841.
19. ↑ Yunas, Idnan; Islam, Md Asiful; Sindhu, Kulandaipalayam N.; Devall, Adam J.; Podesek, Marcelina; Alam, Sayeda Sadia; Kundu, Shoumik; Mammoliti, Kristie-Marie et al. (2025-04-03). "Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis" (in English). The Lancet 405 (10488): 1468–1480. doi:10.1016/S0140-6736(25)00448-9. ISSN 0140-6736. PMID 40188841.
20. ↑ Saraswat, Lucky (2015). "ESHRE2015: Endometriosis associated with a greater risk of complications in pregnancy". European Society of Human Reproduction and Embryology. https://endometriosis.org/news/congress-highlights/eshre2015-endometriosis-associated-with-a-greater-risk-of-complications-in-pregnancy/#:~:text=After adjustments for age and previous pregnancy, results,three times higher for ectopic pregnancy (OR 2.7).
21. ↑ Rohwer, Christa; Rohwer, Anke C; Cluver, Catherine; Ker, Katharine; Hofmeyr, G Justus (2025-01-15). Cochrane Central Editorial Service. ed. "Tranexamic acid for preventing postpartum haemorrhage after vaginal birth" (in en). Cochrane Database of Systematic Reviews 2025 (1). doi:10.1002/14651858.CD007872.pub4. PMID 39812173.
22. ↑ 22.0 22.1 22.2 Peña-Martí, G; Comunián-Carrasco, G (17 October 2007). "Fundal pressure versus controlled cord traction as part of the active management of the third stage of labour.". The Cochrane Database of Systematic Reviews 2010 (4). doi:10.1002/14651858.CD005462.pub2. PMID 17943858.
23. ↑ Soltani, H; Poulose, TA; Hutchon, DR (7 September 2011). "Placental cord drainage after vaginal delivery as part of the management of the third stage of labour.". The Cochrane Database of Systematic Reviews 2011 (9). doi:10.1002/14651858.CD004665.pub3. PMID 21901693.
24. ↑ 24.0 24.1 Abedi, P; Jahanfar, S; Namvar, F; Lee, J (27 January 2016). "Breastfeeding or nipple stimulation for reducing postpartum haemorrhage in the third stage of labour". The Cochrane Database of Systematic Reviews 1 (1). doi:10.1002/14651858.CD010845.pub2. PMID 26816300.
25. ↑ 25.0 25.1 Hofmeyr, GJ; Abdel-Aleem, H; Abdel-Aleem, MA (1 July 2013). "Uterine massage for preventing postpartum haemorrhage". The Cochrane Database of Systematic Reviews 7 (7). doi:10.1002/14651858.CD006431.pub3. PMID 23818022.
26. ↑ "Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial". BMJ (Clinical Research Ed.) (BMJ) 362. Sep 2018. doi:10.1136/bmj.k3546. PMID 30181338.
27. ↑ 27.0 27.1 Gallos, Ioannis D; Yunas, Idnan; Devall, Adam J; Podesek, Marcelina; Tobias, Aurelio; Price, Malcolm J; Oladapo, Olufemi T; Coomarasamy, Arri (2025-04-16). Cochrane Central Editorial Service. ed. "Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis" (in en). Cochrane Database of Systematic Reviews 2025 (4). doi:10.1002/14651858.CD011689.pub4. PMID 40237648.
28. ↑ Liabsuetrakul, Tippawan; Choobun, Thanapan; Peeyananjarassri, Krantarat; Islam, Q. Monir (7 June 2018). "Prophylactic use of ergot alkaloids in the third stage of labour". The Cochrane Database of Systematic Reviews 2018 (6). doi:10.1002/14651858.CD005456.pub3. ISSN 1469-493X. PMID 29879293.
29. ↑ 29.0 29.1 Mousa, HA; Blum, J; Abou El Senoun, G; Shakur, H; Alfirevic, Z (13 February 2014). "Treatment for primary postpartum haemorrhage". The Cochrane Database of Systematic Reviews 2 (2). doi:10.1002/14651858.CD003249.pub3. PMID 24523225.
30. ↑ 30.0 30.1 McDonald, S; Abbott, JM; Higgins, SP (2004). "Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour.". The Cochrane Database of Systematic Reviews 2018 (1). doi:10.1002/14651858.CD000201.pub2. PMID 14973949.
31. ↑ 31.0 31.1 Salati, JA; Leathersich, SJ; Williams, MJ; Cuthbert, A; Tolosa, JE (29 April 2019). "Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage.". The Cochrane Database of Systematic Reviews 2019 (4). doi:10.1002/14651858.CD001808.pub3. PMID 31032882.
32. ↑ 32.0 32.1 32.2 Liabsuetrakul, T; Choobun, T; Peeyananjarassri, K; Islam, QM (7 June 2018). "Prophylactic use of ergot alkaloids in the third stage of labour.". The Cochrane Database of Systematic Reviews 2018 (6). doi:10.1002/14651858.CD005456.pub3. PMID 29879293.
33. ↑ 33.0 33.1 Tunçalp, Ö; Hofmeyr, GJ; Gülmezoglu, AM (15 August 2012). "Prostaglandins for preventing postpartum haemorrhage". The Cochrane Database of Systematic Reviews 2012 (8). doi:10.1002/14651858.CD000494.pub4. PMID 22895917.
34. ↑ 34.0 34.1 Hofmeyr, GJ; Gülmezoglu, AM; Novikova, N; Lawrie, TA (15 July 2013). "Postpartum misoprostol for preventing maternal mortality and morbidity". The Cochrane Database of Systematic Reviews 2013 (7). doi:10.1002/14651858.CD008982.pub2. PMID 23857523.
35. ↑ 35.0 35.1 35.2 Mori, R; Nardin, JM; Yamamoto, N; Carroli, G; Weeks, A (14 March 2012). "Umbilical vein injection for the routine management of third stage of labour". The Cochrane Database of Systematic Reviews 2012 (3). doi:10.1002/14651858.CD006176.pub2. PMID 22419311.
36. ↑ Kumar, Nimisha; Jahanfar, Shayesteh; Haas, David M.; Weeks, Andrew D. (2021-03-11). "Umbilical vein injection for management of retained placenta". The Cochrane Database of Systematic Reviews 2021 (3). doi:10.1002/14651858.CD001337.pub3. ISSN 1469-493X. PMID 33705565.
37. ↑ 37.0 37.1 37.2 Su, LL; Chong, YS; Samuel, M (18 April 2012). "Carbetocin for preventing postpartum haemorrhage". The Cochrane Database of Systematic Reviews 4 (4). doi:10.1002/14651858.CD005457.pub4. PMID 22513931.
38. ↑ "Tranexamic acid for preventing postpartum haemorrhage after vaginal birth". The Cochrane Database of Systematic Reviews 1 (1). 15 Jan 2025. doi:10.1002/14651858.CD007872.pub4. PMID 39812173.
39. ↑ Yaju, Y; Kataoka, Y; Eto, H; Horiuchi, S; Mori, R (26 November 2013). "Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period". The Cochrane Database of Systematic Reviews 2013 (11). doi:10.1002/14651858.CD009328.pub2. PMID 24277681.
40. ↑ "Uterine artery ligation in the control of postcesarean hemorrhage". The Journal of Reproductive Medicine 40 (3): 189–93. March 1995. PMID 7776302.
41. ↑ "Uterine artery embolization: an underused method of controlling pelvic hemorrhage". American Journal of Obstetrics and Gynecology 176 (4): 938–48. April 1997. doi:10.1016/S0002-9378(97)70624-0. PMID 9125624.
42. ↑ "Technical description of the B-Lynch brace suture for treatment of massive postpartum hemorrhage and review of published cases". International Journal of Fertility and Women's Medicine 50 (4): 148–63. 2005. PMID 16405100.
43. ↑ Plauche, WC (1992). "Peripartal Hysterectomy". Obstetrics and Gynecology Clinics of North America (Philadelphia, Pa: WB Saunders) 15 (4): 447–65. PMID 3226676.
44. ↑ Kellie, FJ; Wandabwa, JN; Mousa, HA; Weeks, AD (1 July 2020). "Mechanical and surgical interventions for treating primary postpartum haemorrhage.". The Cochrane Database of Systematic Reviews 2020 (7). doi:10.1002/14651858.CD013663. PMID 32609374.
45. ↑ Cahill, Alison G.; Beigi, Richard; Heine, R. Phillips; Silver, Robert M.; Wax, Joseph R. (December 2018). "Placenta Accreta Spectrum". American Journal of Obstetrics and Gynecology 219 (6): B2–B16. doi:10.1016/j.ajog.2018.09.042. PMID 30471891.
46. ↑ Craig, Elise (December 2013). "A Life Preserver For New Moms". WIRED: 52.
47. ↑ "External aortic compression device: the first aid for postpartum hemorrhage control". The Journal of Obstetrics and Gynaecology Research 35 (3): 453–8. June 2009. doi:10.1111/j.1447-0756.2008.00975.x. PMID 19527382.
48. ↑ "Experience managing postpartum hemorrhage at Minia University Maternity Hospital, Egypt: no mortality using external aortic compression". The Journal of Obstetrics and Gynaecology Research 37 (11): 1557–63. November 2011. doi:10.1111/j.1447-0756.2011.01574.x. PMID 21676082.
49. ↑ Suarez, Sebastian; Conde-Agudelo, Agustin; Borovac-Pinheiro, Anderson; Suarez-Rebling, Daniela; Eckardt, Melody; Theron, Gerhard; Burke, Thomas F. (April 2020). "Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis" (in en). American Journal of Obstetrics and Gynecology 222 (4): 293.e1–293.e52. doi:10.1016/j.ajog.2019.11.1287. PMID 31917139.
50. ↑ 50.0 50.1 Doumouchtsis, S. K.; Papageorghiou, A. T.; Vernier, C.; Arulkumaran, S. (2008). "Management of postpartum hemorrhage by uterine balloon tamponade: Prospective evaluation of effectiveness". Acta Obstetricia et Gynecologica Scandinavica 87 (8): 849–855. doi:10.1080/00016340802179822. PMID 18704777.
51. ↑ Chapter 89 - Balloon tamponade and uterine packing for major PPH from South Australia, Department of Health. 2005
52. ↑ Conde-Agudelo, Agustin; Suarez, Sebastian; Burke, Thomas F. (February 2020). "Condom-catheter uterine balloon tamponade is as efficacious and safe as Bakri balloon for treating postpartum hemorrhage" (in en). American Journal of Obstetrics and Gynecology 223 (1): 138–139. doi:10.1016/j.ajog.2020.02.024. PMID 32109467.
53. ↑ Burke, Tf; Ahn, R; Nelson, Bd; Hines, R; Kamara, J; Oguttu, M; Dulo, L; Achieng, E et al. (August 2016). "A postpartum haemorrhage package with condom uterine balloon tamponade: a prospective multi-centre case series in Kenya, Sierra Leone, Senegal, and Nepal" (in en). BJOG: An International Journal of Obstetrics & Gynaecology 123 (9): 1532–1540. doi:10.1111/1471-0528.13550. PMID 26223284.
54. ↑ Mvundura, Mercy; Kokonya, Donald; Abu-Haydar, Elizabeth; Okoth, Eunice; Herrick, Tara; Mukabi, James; Carlson, Lucas; Oguttu, Monica et al. (May 2017). "Cost-effectiveness of condom uterine balloon tamponade to control severe postpartum hemorrhage in Kenya" (in en). International Journal of Gynecology & Obstetrics 137 (2): 185–191. doi:10.1002/ijgo.12125. PMID 28190262.
55. ↑ Ducloy-Bouthors, Anne-Sophie; Susen, Sophie; Wong, Cynthia A.; Butwick, Alex; Vallet, Benoit; Lockhart, Evelyn (November 2014). "Medical advances in the treatment of postpartum hemorrhage". Anesthesia and Analgesia 119 (5): 1140–1147. doi:10.1213/ANE.0000000000000450. ISSN 1526-7598. PMID 25329026.
56. ↑ "Massive primary postpartum haemorrhage: setting up standards of care". The Journal of the Pakistan Medical Association 56 (1): 26–31. 2006. PMID 16454132. https://www.cmqcc.org/resource/massive-primary-postpartum-haemorrhage-setting-standards-care. Retrieved 2009-12-22. CMQCC guidelines, accessed August 10, 2009
57. ↑ Barbieri RL (2009). "Planning reduces the risk of maternal death. This tool helps". OBG Management 21 (8): 8–10.
58. ↑ Begley, CM; Gyte, GM; Devane, D; McGuire, W; Weeks, A; Biesty, LM (13 February 2019). "Active versus expectant management for women in the third stage of labour.". Cochrane Database of Systematic Reviews 2019 (2). doi:10.1002/14651858.CD007412.pub5. PMID 30754073.
59. ↑ 59.0 59.1 McDonald, SJ; Middleton, P; Dowswell, T; Morris, PS (11 July 2013). "Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes". The Cochrane Database of Systematic Reviews 7 (7). doi:10.1002/14651858.CD004074.pub3. PMID 23843134.
60. ↑ Rabe, H; Gyte, GM; Díaz-Rossello, JL; Duley, L (17 September 2019). "Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes.". The Cochrane Database of Systematic Reviews 2019 (9). doi:10.1002/14651858.CD003248.pub4. PMID 31529790.
61. ↑ "Timing of prophylactic uterotonics for the third stage of labour after vaginal birth". The Cochrane Database of Systematic Reviews (8). August 2010. doi:10.1002/14651858.CD006173.pub2. PMID 20687079.
62. ↑ Alexander, J; Thomas, P; Sanghera, J (2002). "Treatments for secondary postpartum haemorrhage.". The Cochrane Database of Systematic Reviews (1). doi:10.1002/14651858.CD002867. PMID 11869640.
63. ↑ 63.0 63.1 63.2 63.3 63.4 Calvert, C; Thomas, SL; Ronsmans, C; Wagner, KS; Adler, AJ; Filippi, V (2012). "Identifying regional variation in the prevalence of postpartum haemorrhage: a systematic review and meta-analysis". PLOS ONE 7 (7). doi:10.1371/journal.pone.0041114. PMID 22844432. Bibcode: 2012PLoSO...741114C.

## External links

Classification|

* ICD-10: O72
* ICD-9-CM: 666
* MeSH: D006473

|

External resources|

* eMedicine: article/275038

* WHO recommendations for the prevention and treatment of postpartum haemorrhage.. Geneva: World Health Organization. 2012. ISBN 978-92-4-154850-2. https://www.who.int/publications/i/item/9789241548502.
* Postpartum hemorrhage and the B-Lynch technique

* v
* t
* e

Pathology of pregnancy, childbirth and the puerperium (O, 630–679)

Pregnancy|

| Pregnancy with
abortive outcome|

* Abortion
* Ectopic pregnancy
* Abdominal
* Cervical
* Interstitial
* Ovarian
* Heterotopic
* Fetal resorption
* Molar pregnancy
* Miscarriage
* Stillbirth

|

Oedema, proteinuria and
hypertensive disorders|

* Gestational hypertension
* Pre-eclampsia
* HELLP syndrome
* Eclampsia

Other, predominantly
related to pregnancy|

| Digestive system|

* Acute fatty liver of pregnancy
* Gestational diabetes
* Hepatitis E
* Hyperemesis gravidarum
* Intrahepatic cholestasis of pregnancy

|

Integumentary system /
dermatoses of pregnancy|

* Gestational pemphigoid
* Impetigo herpetiformis
* Intrahepatic cholestasis of pregnancy
* Linea nigra
* Prurigo gestationis
* Pruritic folliculitis of pregnancy
* Pruritic urticarial papules and plaques of pregnancy (PUPPP)
* Striae gravidarum

Nervous system|

* Chorea gravidarum

Blood|

* Gestational thrombocytopenia
* Pregnancy-induced hypercoagulability

Maternal care related to the
fetus and amniotic cavity|

* amniotic fluid
* Oligohydramnios
* Polyhydramnios
* Braxton Hicks contractions
* [[Biology:Chorchorion]] / amnion
* Amniotic band syndrome
* Chorioamnionitis
* Chorionic hematoma
* Monoamniotic twins
* Premature rupture of membranes
* Obstetrical bleeding
* Antepartum
* placenta
* Circumvallate placenta
* Monochorionic twins
* Placenta accreta
* Placenta praevia
* Placental abruption
* Twin-to-twin transfusion syndrome

Labor|

* Amniotic fluid embolism
* Cephalopelvic disproportion
* Dystocia
* Shoulder dystocia
* Fetal distress
* Locked twins
* Obstetrical bleeding
* Postpartum
* Pain management during childbirth
* placenta
* Placenta accreta
* Preterm birth
* Postmature birth
* Umbilical cord prolapse
* Uterine inversion
* Uterine rupture
* Vasa praevia

Puerperal|

* Breastfeeding difficulties
* Low milk supply
* Cracked nipples
* Breast engorgement
* Childbirth-related posttraumatic stress disorder
* Diastasis symphysis pubis
* Postpartum bleeding
* Peripartum cardiomyopathy
* Postpartum depression
* Postpartum psychosis
* Postpartum thyroiditis
* Puerperal fever
* Puerperal mastitis

Other|

* Concomitant conditions
* Diabetes mellitus
* Systemic lupus erythematosus
* Thyroid disorders
* Maternal death
* Sexual activity during pregnancy

* Category

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Postpartum bleeding. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Postpartum_bleeding&oldid=4239641"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template